<DOC>
	<DOCNO>NCT00755313</DOCNO>
	<brief_summary>RATIONALE : Gathering information time laboratory test , image scan , assessment test may help doctor learn side effect chemotherapy plan best treatment . PURPOSE : This clinical trial study effect chemotherapy brain woman newly diagnose early-stage breast cancer .</brief_summary>
	<brief_title>Effects Chemotherapy Brain Women With Newly Diagnosed Early-Stage Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To prospectively evaluate acute ( 1 month chemotherapy ) relatively long-term ( 18 month chemotherapy ) effect standard-dose chemotherapy and/or hormonal therapy aromatase inhibition brain function use positron emission tomography ( PET ) glucose metabolism tracer fludeoxyglucose F 18 woman newly diagnose , early stage breast cancer . Secondary - To evaluate acute relatively long-term effect chemotherapy and/or hormonal therapy MRI measurement hippocampal volume , cortical grey matter volume , white matter signal hyperintensities , ventricular volume , whole brain volume patient . - To evaluate acute relatively long-term effect chemotherapy and/or hormonal therapy aromatase inhibition cognitive function patient . - To explore characteristic patient render vulnerable chemotherapy and/or estrogen suppression-induced cognitive decline . OUTLINE : Patients stratify accord plan adjuvant chemotherapy ( chemotherapy hormonal therapy v hormonal therapy v chemotherapy v therapy ) hormone receptor status ( positive v negative ) . Patients ( group A-C ) undergo bioavailable estradiol measurement , PET scan , MRI scan baseline 1 18 month treatment . Patients also undergo cognitive , neuropsychological , sociodemographic , quality life assessment use battery study test questionnaires baseline 1 , 9 , 18 month treatment . Group D participant ( control ) undergo test equivalent interval .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer , meet 1 follow criterion : Group A Stage I , II , III invasive disease Hormone receptorpositive disease Planned adjuvant chemotherapy include anthracycline taxane use either dosedense docetaxel , doxorubicin hydrochloride , cyclophosphamide ( TAC ) regimens without trastuzumab ( HerceptinÂ® ) 4 month ; docetaxel cyclophosphamide ( TC ) without trastuzumab 3 month ; doxorubicin hydrochloride cyclophosphamide ( AC ) 3 month ; doxorubicin hydrochloride , carboplatin , trastuzumab ( TCH ) 4 month ( trastuzumab may give 1 year consider chemotherapy purpose study ) Planned treatment adjuvant aromatase inhibitor ( AI ) 5 year Group B Stage I II invasive disease Planned treatment adjuvant AI without radiotherapy Group C Stage I , II , III disease Hormonereceptor negative Planned adjuvant chemotherapy group A No treatment AI plan Group D Healthy control free major medical psychiatric disorder Not take prescription medication , include hormonereplacement therapy , substance might influence performance neuropsychological test Balanced patient group age , education , ethnicity , sociodemographic background PATIENT CHARACTERISTICS : No history psychiatric illness minor depression No history psychiatric illness minor depression immediate family member No history neurologic disease No history drug alcohol abuse No significant medical illness breast cancer No heart pacemaker metallic implant particle body No heart rhythm disturbance No claustrophobia No prior serious head injury No tattoo permanent cosmetic No unremovable body jewelry No cognitive impairment Able read speak English No condition compromise compliance objective procedure study , judge principal investigator PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy , CNS radiotherapy , intrathecal therapy Premenopausal woman receive aromatase inhibitor must also receive ovarian suppression No concurrent narcotic major antipsychotic medication may impair cognition</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>cognitive/functional effect</keyword>
	<keyword>fatigue</keyword>
	<keyword>long-term effect secondary cancer therapy adult</keyword>
	<keyword>psychosocial effect cancer treatment</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>neurotoxicity</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-negative breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
</DOC>